tetano
Editor, Senior Moderator
Front Genet
. 2022 Nov 29;13:1035796.
doi: 10.3389/fgene.2022.1035796. eCollection 2022.
The role of angiotensin I converting enzyme insertion/deletion polymorphism in the severity and outcomes of COVID-19 patients
Mitra Rezaei[SUP] 1 2 [/SUP], Hadiseh Mohammadpour[SUP] 3 [/SUP], Mahya Eftekhari[SUP] 4 [/SUP], Mihan Pourabdollah[SUP] 5 [/SUP], Farinaz Nasr Azadani[SUP] 6 [/SUP], Payam Tabarsi[SUP] 2 [/SUP], Majid Marjani[SUP] 2 [/SUP], Seyed Ali Ziai[SUP] 7 [/SUP]
Affiliations
Abstract
The pandemic of coronavirus disease in 2019 has led to a global crisis. COVID-19 shows distinct clinical manifestations of the severity of symptoms. Numerous patients with no associated risk factors demonstrate acute respiratory distress syndrome (ARDS). The role of genetic factors in determining the severity and outcome of the disease remains unresolved. The purpose of this study was to see if a correlation exists between Angiotensin I Converting Enzyme (ACE) insertion/deletion (I/D) polymorphism and the severity of COVID-19 patients' symptoms. 120 COVID-19 patients admitted to Masih Daneshvari Hospital in Tehran with their consent to participate entered the study. Based on the World Health Organization classification, patients were divided into moderate and severe groups, which were primarily affected by O[SUB]2[/SUB] saturation levels. The effects of the patients' ACE insertion/deletion polymorphism, background disease, Angiotensin receptor blocker (ARB) drug consumption, and demographic parameters on the severity risk were calculated statistically. The ACE D allele was associated with an increased risk of disease severity (OR = 6.766, p = 0.012), but had no effect on mortality.
Keywords: ACE; COVID-19; SARS-CoV-2; angiotensin I converting enzyme; angiotensin-converting enzyme; insertion/deletion polymorphism; peptidyl dipeptidase A; polymorphism.
. 2022 Nov 29;13:1035796.
doi: 10.3389/fgene.2022.1035796. eCollection 2022.
The role of angiotensin I converting enzyme insertion/deletion polymorphism in the severity and outcomes of COVID-19 patients
Mitra Rezaei[SUP] 1 2 [/SUP], Hadiseh Mohammadpour[SUP] 3 [/SUP], Mahya Eftekhari[SUP] 4 [/SUP], Mihan Pourabdollah[SUP] 5 [/SUP], Farinaz Nasr Azadani[SUP] 6 [/SUP], Payam Tabarsi[SUP] 2 [/SUP], Majid Marjani[SUP] 2 [/SUP], Seyed Ali Ziai[SUP] 7 [/SUP]
Affiliations
- PMID: 36531237
- PMCID: PMC9756080
- DOI: 10.3389/fgene.2022.1035796
Abstract
The pandemic of coronavirus disease in 2019 has led to a global crisis. COVID-19 shows distinct clinical manifestations of the severity of symptoms. Numerous patients with no associated risk factors demonstrate acute respiratory distress syndrome (ARDS). The role of genetic factors in determining the severity and outcome of the disease remains unresolved. The purpose of this study was to see if a correlation exists between Angiotensin I Converting Enzyme (ACE) insertion/deletion (I/D) polymorphism and the severity of COVID-19 patients' symptoms. 120 COVID-19 patients admitted to Masih Daneshvari Hospital in Tehran with their consent to participate entered the study. Based on the World Health Organization classification, patients were divided into moderate and severe groups, which were primarily affected by O[SUB]2[/SUB] saturation levels. The effects of the patients' ACE insertion/deletion polymorphism, background disease, Angiotensin receptor blocker (ARB) drug consumption, and demographic parameters on the severity risk were calculated statistically. The ACE D allele was associated with an increased risk of disease severity (OR = 6.766, p = 0.012), but had no effect on mortality.
Keywords: ACE; COVID-19; SARS-CoV-2; angiotensin I converting enzyme; angiotensin-converting enzyme; insertion/deletion polymorphism; peptidyl dipeptidase A; polymorphism.